Summit and Akeso report ivonescimab’s survival benefit in lung cancer, boosting approval odds and positioning it as a Keytruda challenger.
Latest Ratings for SMMT
DateFirmActionFromTo Nov 2020HC Wainwright & Co.DowngradesBuyNeutral Mar 2020HC Wainwright & Co.Initiates Coverage OnBuy Jun 2018Janney Montgomery ScottDowngradesBuyNeutral